PMID- 36172491
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220930
IS  - 1756-2872 (Print)
IS  - 1756-2880 (Electronic)
IS  - 1756-2872 (Linking)
VI  - 14
DP  - 2022 Jan-Dec
TI  - Antimuscarinics for neurogenic overactive bladder in multiple sclerosis: 
      real-life data.
PG  - 17562872221122484
LID - 10.1177/17562872221122484 [doi]
LID - 17562872221122484
AB  - BACKGROUND: Antimuscarinics (AMs) represent the mainstay of treatment for storage 
      lower urinary tract symptoms (LUTS) but few data are available on their impact in 
      multiple sclerosis (MS) patients. OBJECTIVE: To assess effectiveness and 
      tolerability of AMs in MS patients with neurogenic detrusor overactivity (NDO). 
      METHODS: Sixty consecutive outpatients, who started treatment with AMs at one 
      centre, were recruited. The primary endpoint was change in Patient's Perception 
      of Intensity of Urgency Scale (PPIUS) at 6 months; secondary endpoints were 
      post-void residual urine (PVR) and pads used daily. Incidence and severity of 
      adverse events (AEs) were recorded. RESULTS: Significant reduction (p < 0.001) of 
      mean PPIUS and pads use were detected, as well as a significant increase 
      (p < 0.001) of PVR (143 +/- 42 ml).AEs, recorded in 53% of patients, were 
      frequently multiple and caused suspension of AM in 10% of cases, mainly for 
      xerostomia, which has been the commonest AE (26.6%). Neurological AEs appeared in 
      11.7% of subjects, mostly with oxybutynin. Worsening/onset of voiding LUTS, 
      reported by 8.3% of MS, resulted to be the unique AE correlated to AM dosage. 
      CONCLUSION: This study suggests that AMs are effective in MS patients, but their 
      use should be tailored on every patient as even low dosages can be poorly 
      tolerated. AEs, including neurological ones, are common.
CI  - (c) The Author(s), 2022.
FAU - Andretta, Elena
AU  - Andretta E
AD  - Department of Urology, General Hospital, Dolo (Venice), Italy.
FAU - Finazzi Agro, Enrico
AU  - Finazzi Agro E
AUID- ORCID: 0000-0002-0308-8824
AD  - Department of Surgical Sciences, University of Rome Tor Vergata, Via Montpellier, 
      1, 00133 Rome, Italy.
AD  - Urology Unit, Policlinico Tor Vergata Foundation, Rome, Italy.
FAU - Calabrese, Massimiliano
AU  - Calabrese M
AD  - Department of Neuroscience, Biomedicine and Movements, University of Verona, 
      Verona, Italy.
FAU - Orecchia, Luca
AU  - Orecchia L
AUID- ORCID: 0000-0001-8376-5380
AD  - Urology Unit, Policlinico Tor Vergata Foundation, Rome, Italy.
FAU - Furlan, Antonietta
AU  - Furlan A
AD  - Department of Rehabilitation, General Hospital, Dolo (Venice), Italy.
FAU - Zuliani, Cristina
AU  - Zuliani C
AD  - Department of Neurology, General Hospital, Mirano (Venice), Italy.
LA  - eng
PT  - Journal Article
DEP - 20220924
PL  - England
TA  - Ther Adv Urol
JT  - Therapeutic advances in urology
JID - 101487328
PMC - PMC9510970
OTO - NOTNLM
OT  - antimuscarinics
OT  - lower urinary tract symptoms
OT  - multiple sclerosis
OT  - neurogenic detrusor overactivity
OT  - urgency urinary incontinence
COIS- Competing interests: The author(s) declared the following potential conflicts of 
      interest with respect to the research, authorship, and/or publication of this 
      article: EA received honoraria for advisory board commitment, consultancy, as 
      well as conference travel support from Allergan, Coloplast, Wellspect and 
      Teleflex. EFA received honoraria for advisory board commitment from Laborie and 
      consultancy, as well as conference travel support from Recordati and 
      Pierre-Fabre. MC received honoraria for advisory board commitment, consultancy, 
      as well as conference travel support from Merck, Sanofi-Genzyme, Novartis, Biogen 
      and Roche. LO and AF did not declare any competing interests. CZ received 
      honoraria for advisory board commitment, consultancy, as well as conference 
      travel support from Merck, Sanofi-Genzyme, Novartis and Biogen.
EDAT- 2022/09/30 06:00
MHDA- 2022/09/30 06:01
PMCR- 2022/09/24
CRDT- 2022/09/29 02:19
PHST- 2022/03/01 00:00 [received]
PHST- 2022/08/05 00:00 [accepted]
PHST- 2022/09/29 02:19 [entrez]
PHST- 2022/09/30 06:00 [pubmed]
PHST- 2022/09/30 06:01 [medline]
PHST- 2022/09/24 00:00 [pmc-release]
AID - 10.1177_17562872221122484 [pii]
AID - 10.1177/17562872221122484 [doi]
PST - epublish
SO  - Ther Adv Urol. 2022 Sep 24;14:17562872221122484. doi: 10.1177/17562872221122484. 
      eCollection 2022 Jan-Dec.